Michelle Matzko
Director of Clinical Research; Medical Lead, Prevent Trial at AlloVir - Cambridge, MA, US
Michelle Matzko's Colleagues at AlloVir
Jessica Chinault-Jalboot
Head of Quality and Compliance, GCP/GVP and Regulatory
Michelle Matzko's Contact Details
936-662-3626
316 Huntington Avenue,Boston,Massachusetts,02115,United States
AlloVir
Michelle Matzko's Company Details
AlloVir, formerly ViraCyte, was founded in 2013 and is the leader in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The company's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. AlloVir's technology and manufacturing process enables the potential for the treatment and/or prevention of up to six devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio.